Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequate treatment exists. IFN-γ is an antifibrotic cytokine that may attenuate renal fibrosis. Systemically administered IFN-γ causes side effects that may be prevented by specific drug targeting. Interstitial myofibroblasts are the effector cells in renal fibrogenesis. Here, we tested the hypothesis that cell-specific delivery of IFN-γ to platelet-derived growth factor receptor β (PDGFRβ)-expressing myofibroblasts attenuates fibrosis in an obstructive nephropathy [unilateral ureteral obstruction (UUO)] mouse model. PEGylated IFN-γ conjugated to PDGFRβ-recognizing peptide [(PPB)-polyethylene glycol (PEG)-IFN-γ] was tested in vitro and in vivo for...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Background/Aims: The TLR/MyD88/NF-κB signaling pathway has been successfully used to treat renal int...
PDGF-C is a potent mitogen for fibroblasts in vitro. Transgenic PDGF-C overexpression in the heart o...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-γ i...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Background/Aims: The TLR/MyD88/NF-κB signaling pathway has been successfully used to treat renal int...
PDGF-C is a potent mitogen for fibroblasts in vitro. Transgenic PDGF-C overexpression in the heart o...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis leads to end-stage renal disease demanding renal replacement therapy because no adequ...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-γ i...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Renal fibrosis cannot be adequately treated since anti-fibrotic treatment is lacking. Interferon-gam...
Background/Aims: The TLR/MyD88/NF-κB signaling pathway has been successfully used to treat renal int...
PDGF-C is a potent mitogen for fibroblasts in vitro. Transgenic PDGF-C overexpression in the heart o...